Houston, Texas 77060

  • Breast Cancer


This 2 arm study will compare the efficacy and safety of Taxotere + Xeloda, versus Taxotere alone, following a regimen of Adriamycin plus Cytoxan in women with high-risk breast cancer. Following 4 cycles of Adriamycin and Cytoxan, patients will be randomized to receive either 1)Taxotere 75mg/m2 iv on day 1 and Xeloda 825mg/m2 po bid on days 1-14 of each 3 week cycle or 2) Taxotere 100mg/m2 iv alone on day 1 of each 3 week cycle. The anticipated time on study treatment is until disease progression, and the target sample size is 500+ individuals.


Inclusion Criteria: - female patients 18-70 years of age; - adenocarcinoma of the breast; - previous invasive breast cancer if diagnosed >5 years before entering study; - no evidence of metastatic disease. Exclusion Criteria: - history of severe hypersensitivity reaction to Taxotere; - previous treatment with anthracycline, anthracenedione (mitoxantrone), or taxane; - treatment with fluoropyrimidine (5-fluorouracil) within the last 5 years.



Primary Contact:

Study Director
Clinical Trials
Hoffmann-La Roche

Backup Contact:


Location Contact:

Houston, Texas 77060
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: April 07, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.